🔎 Trials Near Me

መነሻ › T-ሴል ሊምፎማ › ካሊፎርኒያ

በካሊፎርኒያ ለT-ሴል ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች

ለT-ሴል ሊምፎማ የሚደረጉ 13 ጥናቶች በካሊፎርኒያ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በካሊፎርኒያ ውስጥ ያሉ ከተሞች

Official study text (English)

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

  • Cedars-Sinai Medical Center, Los Angeles
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT04803201

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • City of Hope National Medical Center, Duarte
  • University of California, Irvine, Irvine
  • University of California San Francisco, San Francisco
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06561048

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

  • City of Hope National Medical Center, Duarte
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT04752826

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
  • City of Hope Comprehensive Cancer Center, Duarte
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • እና 4 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT06724237

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

  • City of Hope Comprehensive Cancer Cente, Duarte
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT06854653

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

  • Rady Children's Hospital, San Diego
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 18 · ሁሉም ጾታዎች · የተሻሻለው በ10 ኦገስ 2026 · NCT06390319

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

  • City of Hope Medical Center, Duarte
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦገስ 2026 · NCT07293403

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

  • City of Hope Medical Center, Duarte
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ጁላይ 2026 · NCT03011814

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

  • City of Hope Medical Center, Duarte
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ጁን 2026 · NCT07278856

A Registry for People With T-cell Lymphoma

  • City of Hope Cancer Center (Data collection only), Duarte
  • UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego
  • University of California San Francisco (Data collection only), San Francisco
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT05978141

MB-105 in Patients With CD5 Positive T-cell Lymphoma

  • University of San Diego (UCSD)-Moores Cancer Center, San Diego
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ኦክቶ 2025 · NCT06534060

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

  • City of Hope Medical Foundation, Duarte
  • University of Southern California, Los Angeles
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2025 · NCT04234048

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital Orange County, Orange
  • UCSF School of Medicine, San Francisco
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ1 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ6 ዲሴም 2024 · NCT05476770

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።